Beijing Adjusts UEBMI Account Management, Boosting Outpatient Coverage
The Beijing Municipal Medical Insurance Bureau has adjusted the management of Urban Employee Basic Medical...
Junshi Biosciences’ H1 2022 Financials Show Tuoyi Sales Growth Despite Revenue Drop
Shanghai-based Junshi Biosciences (HKG: 1877) reported a 55.26% year-on-year (YOY) revenue decline to RMB 946.05...
Connect Biopharma Completes Phase I Trial of CBP-174 for Itch in Skin Diseases
Sino-US biotech Connect Biopharma Holdings Ltd (NASDAQ: CNTB), headquartered in San Diego, California, and Taicang,...
RoosterBio Taps MBL Beijing Biotech as Exclusive Distributor in China
US-based RoosterBio Inc. has appointed MBL Beijing Biotech, a subsidiary of JSR Life Sciences Company,...
Boehringer, Eli Lilly’s Jardiance Wins NMPA Approval for Heart Failure with Preserved Ejection Fraction
Boehringer Ingelheim and Eli Lilly (NYSE: LLY) announced that China’s National Medical Products Administration (NMPA)...
E-nitiate Biopharma Raises RMB 100M in Series A to Advance Autoimmune Disease Drugs
China-based E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd, a drug developer focused on autoimmune diseases, has raised...
Kangtai Bio Partners with Philippine Firm on Pneumonia Vaccines
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has partnered with an unnamed Philippine enterprise...
MicroPort Scientific Posts 10% Revenue Growth Despite COVID-19 in 2022 Interim Results
China-based MicroPort Scientific Corp. (HKG: 0853) reported unaudited 2022 interim results ending June 30, 2022,...
Merck’s Gardasil 9-Valent HPV Vaccine Approved for Expanded Age Range in China
US-based Merck Sharp & Dohme (MSD; NYSE: MRK) announced that China’s National Medical Products Administration...
Onekdrug Raises Series B+ Funding to Boost Pharmaceutical B2B Services
Hunan Wholesale Pharmaceutical Technology Co., Ltd, operating as Onekdrug, has raised tens of millions of...
Sinocelltech’s Ripertamab Wins NMPA Approval for DLBCL Treatment
China-based Sinocelltech Group Ltd (SHA: 688520) has received New Drug Application (NDA) approval from the...
Fosun Pharma’s H1 2022 Revenue Rises 25.9% on New Drug Launches, Global Expansion
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) reported RMB 21.34 billion (USD 3 billion)...
Clover Biopharma’s SCB-2019 Vaccine Shows Strong Immune Response to Omicron BA.5
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) announced positive Phase II/III trial results for its COVID-19...
Staidson and J&J’s Teclistamab Gain Breakthrough Designation for Hemophilia and Myeloma
The Center for Drug Evaluation (CDE) has indicated that Staidson (Beijing) Pharmaceutical Co., Ltd’s (SHE:...
Fosun Pharma to Invest RMB 1B in Chengdu Vaccine Base
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) announced that its subsidiaries, Shanghai Fosun Pharmaceutical...
InnoCare Pharma and CStone Pharmaceuticals’ Drugs Receive Prioritized CDE Review
The Center for Drug Evaluation (CDE) has granted prioritized review status to InnoCare Pharma’s (HKG:...
Luca Healthcare Raises Pre-Series A Funding for Digital Biomarker R&D
Shanghai-based Luca Healthcare Co., Ltd, a firm specializing in digital biomarkers and therapeutics, has raised...
Biocytogen and Tracon Pharmaceuticals Gain FDA IND Approval for Sarcoma Trial
China-based Biocytogen (Beijing) Co., Ltd and US-based Tracon Pharmaceuticals Inc. (Nasdaq: TCON) announced that the...
Hengrui Medicine’s Dalpiciclib Hits Superiority Criteria in Phase III Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that its Phase III SHR6390-III-302 study...
Ascentage Pharma’s H1 2022 Revenue Surges 636.9% on Olverembatinib Sales
China-based Ascentage Pharma (HKG: 6855) reported a significant increase in revenue for the six months...